EP Patent

EP3539536A1 — A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i

Assigned to Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O O · Expires 2019-09-18 · 7y expired

What this patent protects

The invention relates to a pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form I allowing for preparation of all proportional doses of sunitinib composition for administration to a patient comprising diluent, disintegrant, binder, lubricant wherein…

USPTO Abstract

The invention relates to a pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form I allowing for preparation of all proportional doses of sunitinib composition for administration to a patient comprising diluent, disintegrant, binder, lubricant wherein the composition comprises a macromolecular polymer - hypromellose (HPMC) in amount of 1-5% by weight of the total weight of the composition.The invention also relates to a method of producing pharmaceutical composition of sunitinib or its salt.

Drugs covered by this patent

Patent Metadata

Patent number
EP3539536A1
Jurisdiction
EP
Classification
—
Expires
2019-09-18
Drug substance claim
No
Drug product claim
No
Assignee
Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O O
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.